Skip to main content
. Author manuscript; available in PMC: 2012 Mar 25.
Published in final edited form as: Brain Res. 2011 Jan 26;1382:315–320. doi: 10.1016/j.brainres.2011.01.061

Table 1. Hematocrit in PD mice treated with cTfRMAb-EPO fusion protein.

Weeks of treatment Hematocrit
(%)
0 48.3 ± 1.4
2 53.3 ± 2.5*
3 54.1 ± 2.3*

Data are mean ± SD (n=10 replicates/group).

*

p<0.01 difference from week 0; the difference between the hematocrit at weeks 2 and 3 is not significant (ANOVA).